OMX Copenhagen PI
1.136,59
PKT
-22,62
PKT
-1,95
%
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 17.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.03.20 | A.P. Moeller - Maersk A-S (B) kaufen | Jefferies & Company Inc. | |
| 05.03.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 02.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 25.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.02.20 | A.P. Moeller - Maersk A-S (B) verkaufen | JP Morgan Chase & Co. | |
| 21.02.20 | A.P. Moeller - Maersk A-S (B) Hold | Deutsche Bank AG | |
| 20.02.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 11.02.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.02.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.02.20 | Novo Nordisk Neutral | UBS AG | |
| 06.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 05.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 05.02.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 05.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 31.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 29.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 22.01.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 17.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 17.01.20 | Novo Nordisk Neutral | UBS AG | |
| 17.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 16.01.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.01.20 | Novo Nordisk neutral | Morgan Stanley | |
| 06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk kaufen | Bernstein Research | |
| 20.12.19 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 19.12.19 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 17.12.19 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 12.12.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.12.19 | Novo Nordisk Neutral | UBS AG | |
| 28.11.19 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
| 27.11.19 | Novo Nordisk Reduce | HSBC |